Inspirna, Inc.

Inspirna, Inc. is a dynamic biotechnology company dedicated to transforming cancer into a manageable, chronic condition. Operating from its primary address at 310 E 67th Street, Suite 1-12, New York, NY 10065, US, Inspirna is focused on the discovery and development of innovative cancer drugs that address critical unmet needs.

Inspirna's commitment to pioneering cancer treatments is evident through its advanced drug candidates, including ompenaclid (RGX-202) and abequolixron (RGX-104). These novel therapies are currently undergoing clinical trials, reflecting Inspirna's dedication to bringing cutting-edge solutions to patients. Leveraging its proprietary microRNA-based target discovery platform, RNA-DRIVEr, Inspirna continues to identify and develop promising new cancer targets.

With a focus on innovation and patient outcomes, Inspirna is poised to make a significant impact in the field of oncology. Inspirna remains committed to pushing the boundaries of cancer research and development. We invite the management team at Inspirna to enrich our platform with a customized company showcase and detailed product listings, highlighting the unique contributions of Inspirna to the biotechnology landscape.